HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA appropriations

This article was originally published in The Rose Sheet

Executive Summary

Center for Food Safety and Applied Nutrition Adverse Events Reporting System would receive $7.6 mil. in FY 2003 funding under Senate Agriculture Appropriations bill, which unanimously passed out of committee July 25. CAERS funding represents $2 mil. more than budget request. Measure also provides $2 mil. for botanical research carried out by FDA, U-Miss. center. Bill calls for $149.3 mil. in funding for CFSAN and total FDA funding of $1.39 bil., which is $23.4 mil. more than budget request. Full Senate vote has yet to be scheduled...

You may also be interested in...



CFSAN AER system

Center for Food Safety & Applied Nutrition expects to have new adverse events reporting system for cosmetics, food and color additives and dietary supplements in place by May 2003, FDA reports. CFSAN Adverse Event Reporting System (CAER), which is undergoing pilot testing, will replace existing three AER systems. Older versions will remain in place until new system is implemented, agency says. Beginning on or after Sept. 16, CFSAN will send letters to companies notifying them when an AER involving one of their products has been received. Under Senate Agriculture Appropriations bill, CFSAN's AER system would receive $7.6 mil. in FY 2003 funding (1"The Rose Sheet" Aug. 5, 2002, In Brief)...

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.

UsernamePublicRestriction

Register

RS010498

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel